Shan-Chwen Chang Selected Research

Highly Active Antiretroviral Therapy (HAART)

05/2008	Cytomegalovirus retinitis and immune recovery uveitis in AIDS patients treated with highly active antiretroviral therapy in Taiwanese.
11/2007	Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy.
09/2007	Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance.
04/2007	Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study.
02/2007	Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy.
10/2006	Changes in the clinical spectrum of opportunistic illnesses in persons with HIV infection in Taiwan in the era of highly active antiretroviral therapy.
08/2006	Improved survival of persons with human immunodeficiency virus type 1 infection in the era of highly active antiretroviral therapy in Taiwan.
10/2005	Herpes zoster in HIV-1-infected patients in the era of highly active antiretroviral therapy: a prospective observational study.
11/2004	Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections.
07/2004	Successful discontinuation of secondary prophylaxis for histoplasmosis after highly active antiretroviral therapy.
12/2003	Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy.
12/2003	Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection.
03/2002	Discontinuation of secondary prophylaxis for penicilliosis marneffei in AIDS patients responding to highly active antiretroviral therapy.

Articles by Research Topic

Disease

11	Infection 09/2008 - 03/2003
3	Bacteremia 03/2008 - 09/2007
3	Severe Acute Respiratory Syndrome 05/2005 - 10/2004
2	Acquired Immunodeficiency Syndrome (AIDS) 05/2008 - 03/2002
2	Tuberculosis 08/2007 - 12/2003
2	HIV Infections (HIV Infection) 10/2006 - 12/2003
1	Amebic Dysentery (Amoebic Dysentery) 09/2008
1	Cytomegalovirus Retinitis 05/2008
1	Uveitis 05/2008
1	Hepatitis B 11/2007
1	Hypersensitivity (Allergy) 09/2007
1	Cryptococcosis 09/2007
1	Viremia 02/2007
1	Candidiasis (Moniliasis) 11/2006
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2006
1	Influenza in Birds (Avian Flu) 04/2006
1	Cerebral Malaria 01/2006
1	Fungemia 12/2005
1	Thrombophlebitis 12/2005
1	Herpes Zoster 10/2005
1	Opportunistic Infections (Opportunistic Infection) 11/2004
1	Histoplasmosis 07/2004
1	Meningeal Tuberculosis (Tuberculous Meningitis) 12/2002

Drug/Important Bio-Agent (IBA)

3	AntigensIBA 09/2008 - 05/2005
1	Methicillin (Metin)FDA Link 03/2008
1	isepamicinIBA 12/2007
1	AminoglycosidesIBA 12/2007
1	Panton-Valentine leukocidinIBA 12/2007
1	galactomannanIBA 09/2007
1	HLA-B Antigens (HLA-B)IBA 09/2007
1	abacavir (Ziagen)FDA Link 09/2007
1	PerforinIBA 04/2006
1	Hemagglutinins (Hemagglutinin)IBA 04/2006
1	Mefloquine (Lariam)FDA LinkGeneric 01/2006
1	artesunateIBA 01/2006
1	Antifungal AgentsIBA 12/2005
1	RNA (Ribonucleic Acid)IBA 02/2005
1	Interleukin-8 (Interleukin 8)IBA 10/2004
1	Ribavirin (Virazole)FDA LinkGeneric 10/2004
1	InterleukinsIBA 10/2004
1	AllantoinIBA 07/2004
1	liposomal amphotericin B FDA Link 10/2003
1	Reverse Transcriptase InhibitorsIBA 03/2003
1	efavirenz (Sustiva)FDA Link 03/2003

Therapy/Procedure

13	Highly Active Antiretroviral Therapy (HAART) 05/2008 - 03/2002
1	Transplants (Transplant) 08/2007
1	Neonatal Intensive Care 04/2007
1	Transplantation (Transplant Recipients) 10/2003
1	Drug Therapy (Chemotherapy) 12/2002